Superiority of Bivalirudin over Heparin Anticoagulation Therapy for Extracorporeal Membrane Oxygenation? Too Early to Draw Conclusions

Overview

Journal Heliyon

Specialty Social Sciences

Date 2023 Mar 3

PMID 36865472

Authors

Jie Gu

Hongjie Yu

Dang Lin

Affiliations

Soon will be listed here.

Abstract

Background: We aimed to compare the efficacy and safety of bivalirudin versus heparin as the anticoagulant in patients undergoing extracorporeal membrane oxygenation (ECMO).

Methods: We conducted a search in PubMed, Embase and the Cochrane Library for all the studies in which bivalirudin was compared to heparin as the anticoagulant for ECMO. Efficacy outcomes were defined as the time to reach therapeutic levels, time within therapeutic range (TTR), thrombotic events, circuit thrombosis, circuit exchanges. Safety outcomes were reported as heparin-induced thrombocytopenia (HIT), major bleeding events, minor bleeding events. Other outcomes included hospital length of stay (LOS), ICU LOS, mortality, 30-day mortality and in-hospital mortality.

Results: Ten studies with 1091 patients were included for meta-analysis. A significant reduction in thrombotic events [OR 0.51, 95%CI 0.36,0.73, = 0.0002, I = 0%], major bleeding events [OR 0.31, 95%CI 0.10,0.92, = 0.04, I = 75%] and in-hospital mortality [OR 0.63, 95%CI 0.44,0.89, = 0.009, I = 0%] treated with bivalirudin were found compared with heparin. There were no significant differences between groups regarding the time to reach therapeutic levels [MD 3.53, 95%CI -4.02,11.09, = 0.36, I = 49%], TTR [MD 8.64, 95%CI -1.72,18.65, = 0.10, I = 77%], circuit exchanges [OR 0.92, 95%CI 0.27,3.12, = 0.90, I = 38%], HIT [OR 0.25, 95%CI 0.02,2.52, = 0.24, I = 0%], minor bleeding events [OR 0.93, 95%CI 0.38,2.29, = 0.87, I = 0%], hospital LOS [MD -2.93, 95%CI -9.01,3.15, = 0.34, I = 45%], ICU LOS [MD -4.22, 95%CI -10.07,1.62, = 0.16, I = 0%], mortality [OR 1.84, 95%CI 0.58,5.85, = 0.30, I = 60%] and 30-day mortality [OR 0.75, 95%CI 0.38,1.48, = 0.41, I = 0%].

Conclusion: Bivalirudin probably be a potential choice for ECMO anticoagulation. However, based on the included studies' limitation, the superiority of bivalirudin over heparin for anticoagulation in the ECMO population still require further prospective randomized controlled studies before a definite conclusion.

Citing Articles

Is it time to switch to bivalirudin for ECMO anticoagulation?.

Navaei A, Kostousov V, Teruya J Front Med (Lausanne). 2023; 10:1237601.

PMID: 37671395 PMC: 10476497. DOI: 10.3389/fmed.2023.1237601.

References

Rehers S, Beiderlinden M, Ziegeler S . [Extracorporeal Membrane Oxygenation in Thoracic Surgery: the Anesthesiologist's Perspective]. Zentralbl Chir. 2019; 144(1):86-92. DOI: 10.1055/a-0774-8151. View

Machado D, Garvan C, Philip J, Harrington D, Spiess B, Kelly B . Bivalirudin May Reduce the Need for Red Blood Cell Transfusion in Pediatric Cardiac Patients on Extracorporeal Membrane Oxygenation. ASAIO J. 2020; 67(6):688-696. DOI: 10.1097/MAT.0000000000001291. View

Kaseer H, Soto-Arenall M, Sanghavi D, Moss J, Ratzlaff R, Pham S . Heparin vs bivalirudin anticoagulation for extracorporeal membrane oxygenation. J Card Surg. 2020; 35(4):779-786. DOI: 10.1111/jocs.14458. View

Kini A, Yu J, Cohen M, Mehran R, Baber U, Sartori S . Effect of bivalirudin on aortic valve intervention outcomes study: a two-centre registry study comparing bivalirudin and unfractionated heparin in balloon aortic valvuloplasty. EuroIntervention. 2013; 10(3):312-9. DOI: 10.4244/EIJV10I3A54. View

Dangas G, Lefevre T, Kupatt C, Tchetche D, Schafer U, Dumonteil N . Bivalirudin Versus Heparin Anticoagulation in Transcatheter Aortic Valve Replacement: The Randomized BRAVO-3 Trial. J Am Coll Cardiol. 2015; 66(25):2860-2868. DOI: 10.1016/j.jacc.2015.10.003. View

Weitz J, Hudoba M, Massel D, Maraganore J, Hirsh J . Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest. 1990; 86(2):385-91. PMC: 296739. DOI: 10.1172/JCI114723. View

Pollak U . Heparin-induced thrombocytopenia complicating extracorporeal membrane oxygenation support: Review of the literature and alternative anticoagulants. J Thromb Haemost. 2019; 17(10):1608-1622. DOI: 10.1111/jth.14575. View

Bilen O, Loftis L, Teruya J . Severe thrombotic and bleeding complications in a baby with heterozygous factor V Leiden and acquired von Willebrand disease on ECMO. J Extra Corpor Technol. 2011; 43(2):64-9. PMC: 4680025. View

Teruya J, Hensch L, Bruzdoski K, Adachi I, Hui S, Kostousov V . Monitoring bivalirudin therapy in children on extracorporeal circulatory support devices: Thromboelastometry versus routine coagulation testing. Thromb Res. 2019; 186:54-57. DOI: 10.1016/j.thromres.2019.12.007. View

10.

Thomas J, Kostousov V, Teruya J . Bleeding and Thrombotic Complications in the Use of Extracorporeal Membrane Oxygenation. Semin Thromb Hemost. 2017; 44(1):20-29. DOI: 10.1055/s-0037-1606179. View

11.

Kaushik S, Derespina K, Chandhoke S, Shah D, Cohen T, Shlomovich M . Use of bivalirudin for anticoagulation in pediatric extracorporeal membrane oxygenation (ECMO). Perfusion. 2021; 38(1):58-65. DOI: 10.1177/02676591211034314. View

12.

Ignjatovic V, Mertyn E, Monagle P . The coagulation system in children: developmental and pathophysiological considerations. Semin Thromb Hemost. 2011; 37(7):723-9. DOI: 10.1055/s-0031-1297162. View

13.

Steg P, van t Hof A, Hamm C, Clemmensen P, Lapostolle F, Coste P . Bivalirudin started during emergency transport for primary PCI. N Engl J Med. 2013; 369(23):2207-17. DOI: 10.1056/NEJMoa1311096. View

14.

Bertini P, Guarracino F . Anticoagulation in extracorporeal membrane oxygenation: still a challenge. Minerva Anestesiol. 2019; 86(1):7-8. DOI: 10.23736/S0375-9393.19.14265-4. View

15.

Anantha-Narayanan M, Anugula D, Gujjula N, Reddy Y, Baskaran J, Kaushik M . Bivalirudin versus heparin in percutaneous coronary intervention-a systematic review and meta-analysis of randomized trials stratified by adjunctive glycoprotein IIb/IIIa strategy. J Thorac Dis. 2018; 10(6):3341-3360. PMC: 6051880. DOI: 10.21037/jtd.2018.05.76. View

16.

Rivosecchi R, Arakelians A, Ryan J, Murray H, Ramanan R, Gomez H . Comparison of Anticoagulation Strategies in Patients Requiring Venovenous Extracorporeal Membrane Oxygenation: Heparin Versus Bivalirudin. Crit Care Med. 2021; 49(7):1129-1136. DOI: 10.1097/CCM.0000000000004944. View

17.

Stang A . Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010; 25(9):603-5. DOI: 10.1007/s10654-010-9491-z. View

18.

Lee C, Ansell J . Direct thrombin inhibitors. Br J Clin Pharmacol. 2011; 72(4):581-92. PMC: 3195735. DOI: 10.1111/j.1365-2125.2011.03916.x. View

19.

Monagle P, Barnes C, Ignjatovic V, Furmedge J, Newall F, Chan A . Developmental haemostasis. Impact for clinical haemostasis laboratories. Thromb Haemost. 2006; 95(2):362-72. DOI: 10.1160/TH05-01-0047. View

20.

Taylor T, Campbell C, Kelly B . A Review of Bivalirudin for Pediatric and Adult Mechanical Circulatory Support. Am J Cardiovasc Drugs. 2020; 21(4):395-409. PMC: 7654565. DOI: 10.1007/s40256-020-00450-w. View